Diseases of the Kidney & Urinary Tract, Phase II

Evaluating Biomarker-Guided Medication Changes in Kidney Transplant Patients

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to learn whether ORENCIAÒ is as good as tacrolimus in preventing rejection, and whether there are other benefits or harms associated with ORENCIAÒ treatment.

Trial with
Cedars-Sinai Medical Center
Ages
18 years - 70 years

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Cameron Groshek

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Richard Formica, MD
Professor of Medicine (Nephrology) and Professor of Surgery (Transplant); Director of Transplant Medicine, Internal Medicine; Director Outpatient Transplantation Service, Transplantation Center, Yale New Haven Hospital; Medical Director Adult Kidney Transplantation, Transplantation Center, Yale New Haven Hospital

Sub-Investigator

William Asch, MD/PhD, BA

Last Updated
08/12/2024
Study HIC
#2000033724